Features Partner Sites Information LinkXpress
Sign In
Demo Company

Mouse Explants Generated from Patients' Circulating Tumor Cells Pave Way for Directed Personalized Chemotherapy

By BiotechDaily International staff writers
Posted on 19 Jun 2014
Print article
Image: Histopathologic image of small-cell lung cancer (Photo courtesy of Wikimedia Commons).
Image: Histopathologic image of small-cell lung cancer (Photo courtesy of Wikimedia Commons).
Cancer researchers have isolated circulating tumor cells (CTCs) from patients with small-cell lung cancer (SCLC) and implanted them into immunocompromised mice to use as a model system for developing better treatments for the disease.

SCLC is an aggressive neuroendocrine tumor with early dissemination and poor prognosis that accounts for 15%–20% of lung cancer cases and approximately 200,000 deaths in the United Kingdom each year. Most cases are inoperable, and biopsies to investigate SCLC biology are rarely obtainable. A more promising approach for studying SCLC is by collecting "liquid biopsy" specimens—CTCs, which are prevalent in the blood of SCLC patients.

Investigators at the University of Manchester (United Kingdom) reported in June 1, 2014, online edition of the journal Nature Medicine that CTCs from SCLC patients who either responded to chemotherapy or failed to respond to chemotherapy developed into tumors in immunocompromised mice. The resultant CTC-derived explants (CDXs) mirrored the donor patient's response to platinum and etoposide chemotherapy. Genomic analysis of isolated CTCs revealed considerable similarity to the corresponding CDX.

Senior author Dr. Caroline Dive, professor of pharmacology and pharmacy at the University of Manchester, said, “Access to sufficient tumor tissue is a major barrier to fully understanding the biology of SCLC. This liquid biopsy is straightforward and not invasive so can be easily repeated and will allow us to study the genetics of each lung cancer patient’s individual tumor. It also means that we may have a feasible way of monitoring patient response to therapy, hopefully allowing us to personalize and tailor individual treatment plans to each patient. We can use these models to help us understand why so many SCLC patients acquire resistance to chemotherapy and to search for and test potential new targeted treatments.”

Related Links:

University of Manchester

Print article



view channel
Image: Cryoelectron micrograph reconstruction of the Chikungunya virus (Photo courtesy of the Washington University School of Medicine).

Broadly Neutralizing Antibodies Protect Mice from Alphavirus Infection

While screening a panel of mouse and human monoclonal antibodies (MAbs) that had been raised against Chikungunya virus, researchers identified several with inhibitory activity against multiple other arthritogenic... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more

Lab Technologies

view channel
Image: The new ambr 15 fermentation micro-bioreactor system was designed to enhance microbial strain screening applications (Photo courtesy of Sartorius Stedim Biotech).

New Bioreactor System Streamlines Strain Screening and Culture

Biotechnology laboratories working with bacterial cultures will benefit from a new automated micro bioreactor system that was designed to enhance microbial strain screening processes. The Sartorius... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.